How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Quantitative Structure-Activity Relationship (QSAR) Market
- By Application: Drug Discovery, Toxicity Prediction, Environmental Risk Assessment, Cosmetics Safety Evaluation, Agrochemical Development
- By Model Type: 2D QSAR Models, 3D QSAR Models, Pharmacophore Modeling, Read-Across Models, Machine Learning-Based QSAR
- By End User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic and Research Institutes, Regulatory Agencies
- By Software Deployment: On-Premise QSAR Software, Cloud-Based QSAR Platforms, Open-Source QSAR Tools
- By Molecular Descriptor Type: Physicochemical Descriptors, Topological Descriptors, Electronic Descriptors, Geometrical Descriptors, Quantum Chemical Descriptors
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Drug Discovery leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Quantitative Structure-Activity Relationship (QSAR) Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Application 5
Model Type 5
End User 5
Software Deployment 3
Molecular Descriptor Type 5
Companies profiled
Certara
Simulations Plus Inc.
BIOVIA (Dassault Systèmes)
Schrödinger Inc.
ChemAxon (a part of ChemAxon Ltd.)
Molecular Networks GmbH
Optibrium Ltd.
Lhasa Limited
ChemDiv Inc.
MolSoft LLC
Chemoinformatics Solutions Inc.
ACD/Labs
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Certara
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Simulations Plus Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →BIOVIA (Dassault Systèmes)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Schrödinger Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ChemAxon (a part of ChemAxon Ltd.)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Molecular Networks GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Optibrium Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Lhasa Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →ChemDiv Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →MolSoft LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Chemoinformatics Solutions Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →ACD/Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →OpenEye Scientific Software
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →ChemAxon
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BioSolveIT GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,383M by 2033 · 8.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Drug Discovery44.4
- Toxicity Prediction9.6
- Environmental Risk Assessment18.4
- Cosmetics Safety Evaluation10.1
- Agrochemical Development17.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$422.1M → $824.1M · 8.7%
Europe$294.2M → $517.9M · 7.3%
Asia Pacific$268.6M → $465.1M · 7.1%
Latin America$166.3M → $296.7M · 7.5%
Middle East and Africa$127.9M → $248.6M · 8.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.042026
8.042027
8.072028
8.072029
8.092030
8.092031
8.112032
8.122033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Certara23.6
- Simulations Plus Inc.12.2
- BIOVIA (Dassault Systèmes)10.5
- Schrödinger Inc.13.5
- ChemAxon (a part of ChemAxon Ltd.)5.3
- Molecular Networks GmbH7.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Application11.8%
Model Type22.9%
End User10.6%
Software Deployment24.9%
Molecular Descriptor Type29.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.0
- Europe22.0
- Asia Pacific19.8
- Latin America12.6
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Certara | 81 | 83 | 75 | 87 | 76 | 74 | 79 |
| Simulations Plus Inc. | 79 | 76 | 81 | 69 | 88 | 87 | 80 |
| BIOVIA (Dassault Systèmes) | 74 | 78 | 78 | 67 | 71 | 86 | 76 |
| Schrödinger Inc. | 69 | 62 | 80 | 73 | 69 | 58 | 69 |
| ChemAxon (a part of ChemAxon Ltd.) | 70 | 66 | 60 | 64 | 57 | 67 | 64 |
| Molecular Networks GmbH | 48 | 69 | 50 | 62 | 66 | 67 | 60 |
| Optibrium Ltd. | 42 | 62 | 58 | 55 | 51 | 42 | 52 |
| Lhasa Limited | 36 | 36 | 38 | 42 | 58 | 53 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Certara
- Simulations Plus Inc.
- BIOVIA (Dassault Systèmes)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Certara | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Simulations Plus Inc. | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| BIOVIA (Dassault Systèmes) | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Schrödinger Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| ChemAxon (a part of ChemAxon Ltd.) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Molecular Networks GmbH | ◐ | ◐ | − | ◐ | ◐ | ✓ |
| Optibrium Ltd. | − | ◐ | − | − | ◐ | − |
| Lhasa Limited | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Simulations Plus Inc.80
2Certara79
3BIOVIA (Dassault Systèmes)76
4Schrödinger Inc.69
5ChemAxon (a part of ChemAxon Ltd.)64
6Molecular Networks GmbH60
7Optibrium Ltd.52
8Lhasa Limited44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CertaraSimulations Plus Inc.
Challenger2
Strong scale, closing on the leaders.
BIOVIA (Dassault Systèmes)Schrödinger Inc.
Contender2
Focused players with pockets of strength.
ChemAxon (a part of ChemAxon Ltd.)Molecular Networks GmbH
Niche2
Specialists in a single segment or region.
Optibrium Ltd.Lhasa Limited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Application in North America, then scale across Quantitative Structure-Activity Relationship (QSAR) Market — a $626M beachhead inside a $8.38B market.
Beachhead (SOM)$626Mobtainable near-term
Serviceable (SAM)$3.35Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Drug Discovery
Best fit — highest urgency & budget in Application.
Economic buyer76 fit
Toxicity Prediction
Strong fit — clear ROI and a fast path to value.
End user65 fit
Environmental Risk Assessment
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Model Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Quantitative Structure-Activity Relationship (QSAR) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified20%
Evaluation15%
Closed-won6%
$17.8KCAC
$67KLTV
3.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Quantitative Structure-Activity Relationship (QSAR) Market is a durable-growth opportunity — $6.33B by 2033, compounding at 9.0%.
TAM · 2025$3.18Btoday
TAM · 2033$6.33Bforecast
CAGR9.0%2027–2033
Cumulative$41.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.33BTotal addressable market
SAM$2.55BServiceable available market
SOM$484MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.0% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.33BLarge & growingTAM by 2033 at 9.0% CAGR
$2.55BServiceable nowreachable with today’s model
$484MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.94BBear5.8% CAGR
$6.33BBase9.0% CAGR
$8.10BBull11.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Model Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Quantitative Structure-Activity Relationship (QSAR) Market — a $9.25B market by 2033. Plan: grow share from 6.2% to 11.7%.
Market size · 2033$9.25Btotal addressable
Market CAGR6.9%2027–2033
Target share11.7%from 6.2% today
Revenue ambition$1.08Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.2% | 11.7% | At risk |
| Revenue | $592M | $1.08B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.2% | 39.0% | Behind |
| Customer retention | 90.6% | 92.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Model Type capability
A defensible second engine — invest in Model Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Model Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $150M capacity & capability investment
- Greenlight bolt-on M&A in Model Type
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Quantitative Structure-Activity Relationship (QSAR) Market conversation — a $3.19B market you can size, segment and defend in minutes.
Market size · 2033$3.19Btotal opportunity
Growth7.9%CAGR to 2033
Addressable buyers1,481+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 2 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
CertaraSimulations Plus Inc.BIOVIA (Dassault Systèmes)Schrödinger Inc.ChemAxon (a part of ChemAxon Ltd.)Molecular Networks GmbHOptibrium Ltd.Lhasa Limited+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Quantitative Structure-Activity Relationship (QSAR) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Quantitative Structure-Activity Relationship (QSAR) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Quantitative PCR Reagent Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportQuantitative PCR Kit Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportQuantitative PCR Equipment Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportQuantitative Pathology Imaging Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportQuantitative Nuclear Magnetic Resonance (qNMR) Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportQuantitative Neuromuscular Transmission Monitor Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportQuantitative Immunoassay Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportQuantitative Immunoassay Analyzer Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportQuantitative Dispensing Machine Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportQuantitative Digital Electroencephalograph Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportQuantitative Brain Function Imaging Device Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportQuality Safety Reporting Systems Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.